Human FVIII expression using a HAC vector toward stem cell-mediated gene therapy for hemophilia A
| Project/Area Number |
20890130
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (Start-up)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
KUROSAKI Hajime Tottori University, 大学院・医学系研究科, 助教 (70464295)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,302,000 (Direct Cost: ¥2,540,000、Indirect Cost: ¥762,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,742,000 (Direct Cost: ¥1,340,000、Indirect Cost: ¥402,000)
|
|---|
| Keywords | 染色体 / 血友病 / iPS細胞 / ヒト人工染色体ベクター / 細胞補充 |
|---|
| Research Abstract |
We sought to elucidate the potential usefulness of a human artificial chromosome (HAC) vector carrying the human FVIII cDNA for gene therapy of Hemophilia A. We have demonstrated the production and secretion of FVIII using the HAC vector carrying multi copies of FVIII in the hemophiliac mouse derived stem cell. This develops promising gene therapies for hemophilia A.
|
Report
(3 results)
Research Products
(9 results)
